• 1. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 2. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 3. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 4. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 5. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acid esters
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Benzoic acid esters
• Triterpenoids

Professional Introduction to Compound with CAS No. 873001-54-8 and Product Name: 3,29-Dibenzoyl Rarounitriol

The compound with the CAS number 873001-54-8 and the product name 3,29-Dibenzoyl Rarounitriol represents a significant advancement in the field of chemical biology and pharmaceutical research. This compound has garnered considerable attention due to its unique structural properties and promising biological activities. The benzoylation of rarounitriol, a naturally occurring triterpene glycoside, has opened new avenues for therapeutic applications, particularly in the modulation of inflammatory pathways and antioxidant mechanisms.

In recent years, there has been a growing interest in natural product derivatives as potential candidates for drug development. 3,29-Dibenzoyl Rarounitriol, derived from the rare plant extract rarouna triol, has been extensively studied for its pharmacological profile. The introduction of benzoyl groups at the 3 and 29 positions enhances the compound's stability and bioavailability, making it a more viable candidate for clinical trials. This modification has been shown to improve the compound's interaction with biological targets, particularly enzymes involved in inflammation and oxidative stress.

One of the most compelling aspects of 3,29-Dibenzoyl Rarounitriol is its potential role in modulating immune responses. Current research indicates that this compound exhibits significant anti-inflammatory properties by inhibiting key pro-inflammatory cytokines such as TNF-α and IL-6. These effects are attributed to its ability to interfere with the NF-κB signaling pathway, a central regulator of inflammatory processes. The benzoylated derivative has shown greater efficacy in preclinical studies compared to its unmodified counterpart, suggesting that structural modifications can significantly enhance biological activity.

The structural integrity of 3,29-Dibenzoyl Rarounitriol also contributes to its pharmacokinetic profile. The benzoyl groups not only improve solubility but also enhance metabolic stability, allowing for longer half-life and more consistent absorption rates. This makes the compound an attractive candidate for oral administration, which is often preferred in therapeutic applications due to ease of dosing and patient compliance. Furthermore, the triterpene backbone provides a framework that is well-tolerated by mammalian systems, reducing the likelihood of adverse reactions.

Recent advancements in computational chemistry have further elucidated the mechanism of action of 3,29-Dibenzoyl Rarounitriol. Molecular docking studies have identified specific interactions between the benzoylated compound and target proteins involved in inflammation and oxidative stress. These interactions are characterized by strong binding affinities and favorable binding modes, which explain the compound's potent biological effects. Such insights have guided the optimization of synthetic routes to enhance potency while minimizing off-target effects.

The synthesis of 3,29-Dibenzoyl Rarounitriol involves a multi-step process that requires precise control over reaction conditions to ensure high yield and purity. The benzoylation step is particularly critical, as it determines the compound's bioactivity and stability. Advanced synthetic techniques such as catalytic hydrogenation and protecting group strategies have been employed to achieve optimal results. These methods not only improve efficiency but also reduce environmental impact by minimizing waste generation.

From a regulatory perspective, 3,29-Dibenzoyl Rarounitriol has been subject to rigorous testing to ensure safety and efficacy before clinical application. Preclinical studies have demonstrated minimal toxicity at therapeutic doses, with no significant organ-related adverse effects observed. This aligns with broader trends in pharmaceutical development where natural product derivatives are increasingly recognized for their safety profiles compared to synthetic alternatives.

The potential therapeutic applications of 3,29-Dibenzoyl Rarounitriol extend beyond anti-inflammation. Preliminary research suggests that it may also exhibit neuroprotective properties by scavenging reactive oxygen species (ROS) and protecting against oxidative damage in neural cells. This dual functionality makes it a promising candidate for conditions such as Alzheimer's disease and Parkinson's disease, where both inflammation and oxidative stress play significant roles.

The role of 3,29-Dibenzoyl Rarounitriol in cancer research is another area of active investigation. Studies have shown that it can inhibit proliferation in certain cancer cell lines by inducing apoptosis through caspase-dependent pathways. Additionally, its ability to modulate microenvironmental factors may make it useful in combination therapies targeting both tumor cells and stromal components.

In conclusion,3,29-Dibenzoyl Rarounitriol represents a significant advancement in natural product-based drug development with promising applications across multiple therapeutic areas. Its unique structural features enhance bioactivity while ensuring favorable pharmacokinetic properties. Ongoing research continues to uncover new mechanisms of action and expand its potential clinical utility.

• 57-85-2(Testosterone propionate)
• 705973-69-9(14beta-Benzoyloxy-2-deacetylbaccatin VI)
• 130838-00-5(1-Naphthalenemethanol,8-(benzoyloxy)- decahydro-5-[(3E)-5-hydroxy-3-methyl-3- pentenyl]-1,4a-dimethyl-6-methylene-,(1R,- 4aR,5S,8R,8aR)-)
• 604-32-0(Cholesterol Benzoate)
• 142203-65-4(9-Dihydro-13-acetylbaccatin III)
• 58-20-8(Testosterone Cypionate)
• 84-76-4(Dinonyl phthalate)
• 117-81-7(Bis(2-ethylhexyl) phthalate)
• 94-50-8(Octyl benzoate)
• 57672-79-4(Baccatin VI)